Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imsidolimab in Generalized Pustular Psoriasis
NCT03619902Phase 2Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Jan 2019
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of imsidolimab in generalized pustular psoriasis (GPP), sponsored by Vanda Pharmaceuticals Inc.. Started Jan 2019; status: completed.
02
Drugs
imsidolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT03619902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03619902.